Patients with HIV-1 RNA <40 copies/mL and target not detected outcome similar with dual DTG/3TC vs triple or quadruple TAF-based regimens.
At Week 124, 80% of patients still demonstrated virologic suppression on monthly injectable cabotegravir + rilpivirine, with no new safety signals since the Week 96 analysis.
After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.
Large, retrospective analysis illustrates viral suppression with and tolerability of dolutegravir-based regimens in children and adolescents who were treatment naive or suppressed on previous regimens.
In this real-world study, healthcare staff across a variety of clinic types found the implementation of monthly injectable cabotegravir + rilpivirine both feasible and acceptable despite disruptions due to COVID-19.
Reduced doses and/or shorter durations of linezolid are associated with similar efficacy but improved safety.
After 2-week oral lead-in, treatment with oral or subcutaneous lenacapavir plus FTC/TAF associated with high rates of virologic suppression.
Adherence to the dapivirine vaginal ring and oral PrEP was higher than anticipated over 12 months, with rates reaching 50% to 59% depending on the modality.
While the number of PrEP breakthrough infections was small, there was a high frequency of ART resistance in HIV-infected persons on TDF-based PrEP in Kenya, Zimbabwe, Eswatini, and South Africa.
In patients with multidrug-resistant HIV-1 infection, lenacapavir in combination with an optimized background regimen demonstrated a high rate of virologic suppression, a clinically meaningful increase in CD4+ cell count, and no discontinuation of study therapy due to adverse events through 26 weeks.